SG Americas Securities
ROIV icon

SG Americas Securities’s Roivant Sciences ROIV Stock Holding History

SG Americas Securities’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.29M Sell
177,593
-463,330
-72% -$13.7M ﹤0.01% 1010
2026
Q1 		$17.8M Buy
640,923
+617,629
+2,651% +$15.9M 0.02% 588
2025
Q4 		$505K Sell
23,294
-26,868
-54% -$530K ﹤0.01% 2485
2025
Q3 		$759K Buy
50,162
+6,761
+16% +$83.7K ﹤0.01% 1740
2025
Q2 		$489K Buy
43,401
+26,050
+150% +$282K ﹤0.01% 1692
2025
Q1 		$175K Buy
+17,351
New +$188K ﹤0.01% 2629
2024
Q4 		– Sell
-29,925
Closed -$345K – 3542
2024
Q3 		$345K Sell
29,925
-14,712
-33% -$167K ﹤0.01% 2020
2024
Q2 		$472K Buy
+44,637
New +$489K ﹤0.01% 1712
2023
Q4 		– Sell
-9,999
Closed -$117K – 3391
2023
Q3 		$117K Sell
9,999
-75,632
-88% -$855K ﹤0.01% 2691
2023
Q2 		$863K Sell
85,631
-8,315
-9% -$74.4K 0.01% 1129
2023
Q1 		$693K Buy
93,946
+8,839
+10% +$72.8K 0.01% 1453
2022
Q4 		$680K Buy
+85,107
New +$473K 0.01% 1271

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

SG Americas Securities's ROIV Position: Q2 2026 in Review

SG Americas Securities reduced its Roivant Sciences (ROIV) stake by 72% in Q2 2026, selling an estimated $13.7M and leaving 177,593 shares worth $6.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1010.

SG Americas Securities first reported a position in ROIV in Q4 2022 and has held it in 12 quarters since. The position peaked at $17.8M in Q1 2026. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • SG Americas Securities held 177,593 shares of Roivant Sciences worth $6.29M as of Q2 2026.
  • SG Americas Securities sold 463,330 Roivant Sciences shares in Q2 2026, an estimated $13.7M.
  • Roivant Sciences made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1010 holding.
  • SG Americas Securities first reported a position in Roivant Sciences in Q4 2022 and has held it in 12 quarters since.
  • SG Americas Securities's Roivant Sciences position peaked at $17.8M in Q1 2026.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.